Hematology/Oncology, Veterans Affairs North Texas Healthcare System, Dallas, Texas, USA.
Am J Med Sci. 2010 Jan;339(1):68-76. doi: 10.1097/MAJ.0b013e3181bccef5.
Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a significant cause of cancer mortality in the United States and across the world. With appropriate treatment, about 20% of patients who present with limited stage SCLC can be cured of their disease. Unfortunately, the outcome for the remainder of patients is extremely poor. The only significant advance in extensive stage SCLC in the past 2 decades is the recent discovery that prophylactic cranial irradiation improves survival in those patients whose disease has responded to initial chemotherapy. Numerous attempts to enhance the antitumor effects of traditional chemotherapy for SCLC have not been successful. As the understanding of the biology of SCLC increased, a number of rational molecular targets for therapy have been identified. Although initial attempts at "targeted therapy" in SCLC have been unsuccessful, several newly identified targets hold promise and give hope that significant improvements in therapy for this challenging disease are not far away.
尽管小细胞肺癌(SCLC)的发病率在过去 30 年中有所下降,但它仍是美国和全球癌症死亡的主要原因。通过适当的治疗,约 20%的局限期 SCLC 患者可以治愈。不幸的是,其余患者的预后极差。在过去 20 年中,广泛期 SCLC 唯一显著的进展是最近发现预防性颅脑照射可提高对初始化疗有反应的患者的生存率。许多试图增强 SCLC 传统化疗抗肿瘤作用的尝试都没有成功。随着对 SCLC 生物学的认识不断提高,已经确定了许多合理的治疗靶点。尽管 SCLC 的“靶向治疗”最初尝试失败,但一些新确定的靶点有希望,让人们有理由相信,这种具有挑战性的疾病的治疗将取得重大进展。